Trial Profile

A Phase II, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of HB0025 in Patients With Advanced Renal Cancer

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 09 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs HB 0025 (Primary)
Indications Carcinoma; Renal cancer
Focus Therapeutic Use
Sponsors Huabo Biopharm

Most Recent Events

04 Jun 2024 Results(As of Dec 25, 2023, n=17) exploring safety and efficacy of HB0025 in advanced renal cell carcinoma pts that failed standard treatment, presented at the 60th Annual Meeting of the American Society of Clinical Oncology
30 Jan 2024 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com